Welcome to our dedicated page for Intelgenx Technologies news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on Intelgenx Technologies stock.
Intelgenx Technologies Corp (IGXT) specializes in advanced drug delivery solutions for pharmaceutical partners worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's proprietary technologies, strategic collaborations, and regulatory progress.
Track critical developments including formulation advancements, clinical trial milestones, manufacturing expansions, and partnership announcements. Our curated collection ensures timely access to verified press releases and objective reporting on IGXT's role in enhancing therapeutic outcomes through innovative delivery systems.
Discover updates spanning key operational areas: regulatory submissions for improved drug formulations, strategic licensing agreements with global partners, and manufacturing scale-up initiatives for optimized production. Bookmark this page for direct access to Intelgenx's official communications and third-party analyses of their pharmaceutical development progress.
IntelGenx Technologies Corp. (TSX:IGX) has announced the receipt of a fourth term loan tranche amounting to U.S.$3 million from atai Life Sciences. This funding follows an amended and restated secured loan agreement. The loan is guaranteed by IntelGenx, which focuses on developing pharmaceutical films using its advanced technologies. IntelGenx aims to provide innovative drug delivery solutions that address unmet medical needs, enhancing patient care.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has announced a research collaboration with the University of Prince Edward Island (UPEI) to assess the palatability and acceptance of its VetaFilm™ platform for administering medications to dogs and cats. The study will investigate acceptance rates of various formulations, flavor preferences, and ease of administration. CEO Dr. Horst G. Zerbe emphasized the advantages of VetaFilm™ in reducing medication administration issues, suggesting its potential for commercial success in the veterinary market.
IntelGenx Corp. (TSX:IGX) has received FDA acceptance for its Class 2 response to the 2020 Complete Response Letter concerning RIZAFILM® VersaFilm®. The FDA has set a PDUFA goal date of April 17, 2023 for the NDA review. The CEO, Dr. Horst G. Zerbe, expressed optimism about making RIZAFILM® available for acute migraine patients in the U.S.
IntelGenx is known for its innovative pharmaceutical film technologies aimed at addressing unmet medical needs.
IntelGenx Technologies Corp. (TSX:IGX) has rescheduled its third quarter 2022 conference call to November 11, 2022, at 8:00 a.m. ET, moving it from the original date. This call will be critical for investors to evaluate the company's latest financial performance and operational updates. The event can be accessed via phone or through a live broadcast on IntelGenx’s website. The company, noted for its innovative pharmaceutical film technologies, continues to focus on addressing unmet medical needs through its advanced product pipeline.
IntelGenx Technologies Corp. (TSX:IGX, OTCQB:IGXT) reported Q3 2022 results, revealing a revenue decline to $142,000, down 76% from $593,000 in Q3 2021. The company reported a net comprehensive loss of $3.0 million, worsening from $2.2 million in the prior year. Adjusted EBITDA loss increased to $2.2 million. Significant developments included a provisional patent application for new cannabinoid formulations, a GDUFA date for Buprenorphine Buccal Film, and progress in clinical trials for Alzheimer’s. Cash and short-term investments totaled $4.7 million.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has announced a Feasibility Study & Development Agreement with an unidentified animal health company. This collaboration focuses on creating a VetaFilm™-based oral film formulation containing CBD for companion animals. IntelGenx is set to supply a CBD-infused prototype for clinical evaluation, potentially leading to a commercial agreement. The global CBD pet market is projected to grow at a CAGR of 58.9%, reaching $4.79 billion by 2028, indicating significant market opportunity for IntelGenx.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) is set to release its third quarter 2022 financial results after market close on November 10, 2022. The results will be discussed in a conference call hosted by CEO Dr. Horst G. Zerbe and CFO Andre Godin at 4:30 p.m. ET. This update is crucial for stakeholders as the company focuses on its innovative pharmaceutical films, including technologies like VersaFilm® and VetaFilm™, addressing unmet medical needs.
IntelGenx Corp. (TSX:IGX) has filed a new provisional patent application with the USPTO for 'Advanced Oral Film Formulations.' This patent focuses on cannabinoid administration for faster onset, supporting the development of non-combustible cannabis products. The application allows for the inclusion of THC and CBD in buccal and sublingual films, optimizing the effects. Dr. Horst G. Zerbe noted this filing enhances their intellectual property portfolio. IntelGenx is committed to expanding this technology internationally as the patent progresses.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) announced on October 25, 2022, the submission of an ANDA for its Buprenorphine Buccal Film, developed in partnership with Chemo Research. The FDA has set a GDUFA date of April 28, 2023, for review. This product is a generic version of Belbuca®, designed for long-term pain management. With global annual sales of Belbuca® reaching $315 million as of July 2022, IntelGenx aims to offer an affordable alternative. The company looks forward to a favorable FDA decision and potential commercialization of the product.
IntelGenx Corp. announced the issuance of U.S. Patent No. 11,471,406 by the USPTO, enhancing its intellectual property portfolio related to its VersaFilm® oral film technology. This patent, valid until at least 2038, focuses on modulating drug absorption for sublingually administered pharmaceuticals, including cannabinoids. The patent reinforces IntelGenx's commitment to innovation in drug delivery and opens opportunities for new products.
